z-logo
open-access-imgOpen Access
Inhaled Insulin: Intrapulmonary or Intranasal?
Author(s) -
Danish Ahmed,
Sweta Kumari,
Shruti Mishra,
Shivangi Jaiswal
Publication year - 2012
Publication title -
nature precedings
Language(s) - English
Resource type - Journals
ISSN - 1756-0357
DOI - 10.1038/npre.2012.7115.1
Subject(s) - medicine , transdermal , nasal administration , insulin , buccal administration , drug , anesthesia , pharmacology
Initial attempts delivered the insulin hormone intramuscularly, intravenously, and eventually subcutaneously. Other routes of administration of the drug were explored. These included oral, rectal, sublingual, buccal, transdermal, vaginal, intramuscular, intrapulmonary, and intranasal delivery systems. The purpose of these latter studies was to determine a noninjectable method to deliver insulin to patients with type 1 and 2 diabetes that would effectively lower blood sugar, control hemoglobin A1c (in much later studies), and allow patients a simpler, less invasive, and more direct control oftheir underlying disease process. In January 2006 the United States Food and Drug Administration approved Exubera (Pfizer Pharmaceuticals, New York, NY) as the first pulmonary inhaled insulin. In actuality attempts to explore various methods to deliver insulin using intrapulmonary delivery had occurred since1925.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom